European Psychiatry - Volume 33 - March 2016

682 / 812

S678 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
Introduction Bupropion is a dual antidepressant, a nore-
pinephrine and dopamine reuptake inhibitor. Its main use is in
affective disorders as major depression. Antidepressants have been
commonly associated with sexual side effects in the libido, sex-
ual arousal, orgasm and erectile function. Bupropion has negative
influence in sexual function, even it could increase the libido. Due
to this, it could be a good option in patients with active sexual life
and affective disorder.
Clinical report A58-year-old femalewith a long history of depres-
sion disorder for 5 years. History of lots of side effects with different
treatments, sexual dysfunction with serotonin-antidepressants.
Treated with bupropion SR 150mg/day and alprazolam, she suf-
fered a relapse. The bupropion was increased to 300mg/day. Three
days later she appeared in the consultation room, presented a sense
of pre-orgasmic of 72 hours of evolution, high increased libido,
tiredness, muscle tension and insomnia. This sense did not improve
after the sexual act. It had never happened previously. The side
effect improved when the bupropion was reduced to 150mg/day
and disappeared with its withdrawal.
Conclusions The case made a relationship between the increased
of bupropion’s dose and the appearance of unusual sexual side
effects (increased of libido and pre-orgasmic sense). Not only
bupropion is one of the antidepressants that do not cause sexual
dysfunction, if not it was reported in some trials that could be a
treatment against this dysfunction due to its prosexual effects. The
mechanism is unknown but could be related with norepinephrine
or dopamine transmission.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1029
Lithium treatment and thyroid
dysfunction – data from an inpatient
psychiatric department
M. Lázaro ∗ ota oreira lves . Nobre
1 Centro Hospitalar Psiquiátrico de Lisboa, Clínica 5, Lisbon, Portugal
2 Área de Pedopsiquiatria, Centro Hospitalar Lisboa Central, H.D.
Estefânia, Lisboa, Portugal
∗ Corresponding author.
Introduction Lithium is among the most effective therapies
for bipolar disorder. Lithium treatment may cause hypothy-
roidism, goiter or to a lesser extent hyperthyroidism, since it
can affect several aspects of thyroid functioning. The prevalence
of lithium-associated hypothyroidism varies extensively between
studies, reaching up to 47%, and affecting more females than
males (5:1).
Objective Determine the prevalence of thyroid dysfunction in an
acute inpatient psychiatric department dedicated to affective dis-
orders and its association with lithium therapy.
Aims To review the relation between lithium treatment and thy-
roid dysfunction.
Methods Observational, descriptive and retrospective study with
clinical and laboratorial data concerning all inpatient episodes of
2015 in our Psychiatric Department. A non-systematic literature
search was performed in PubMed.
Results The present study documented a high prevalence of thy-
roid dysfunction, particularly in women. Most cases were due
to either hypothyroidism or subclinical hypothyroidism. Patients
treated with lithium were more often under thyroid hormone
replacement therapy (levothyroxine).
Conclusions The evidence that lithium treatment is associated
with hypothyroidism is well established and this condition is easily
treatable with levothyroxine. This study highlights the importance
of baseline screening of thyroid function and regular long-term
monitoring in patients treated with lithium.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1030
Do patients with psychotic disorders
who smoke need higher dose of
antipsychotic?
G. Ledesma-Iparraguirre ∗ opez-Romeo hicart-Rosell
N. Pastrana-Rocher , G. Saenz-Navarrete , N. Del Cacho ,
V. Barneda , J. Usall , E. Rubio-Abadal
1 Research and Development Unit, Parc Sanitari Sant Joan de Déu,
Sant Boi de Llobregat, Barcelona, Spain
2 Grup de Treball de Dona i Salut Mental, GTRDSM, Barcelona, Spain
3 Centro de investigación biomédica en red de salud mental,
CIBERSAM, Barcelona, Spain
∗ Corresponding author.
Introduction Prevalence of tobacco use in patients with psychotic
disorders (PD) is 40–70%. It has been described use of tobacco
induces Cytochrome P450 activity, increasing some antipsychotic
drugs metabolism, thus reduces their plasma levels.
Aim We carried out the present study to analyze the associa-
tion between tobacco use and doses of antipsychotics in patients
with PD and to determine whether patients suffering from PD who
smoke may require antipsychotic dose adjustments.
Methods We designed a cross-sectional study of patients
between 18 and 55 years, with a PD, treatedwith the same antipsy-
chotic and dose for the last 6 months:
– consumption of cigarettes per day was determined;
– the doses of the used antipsychotic drugs were converted into
chlorpromazine equivalents;
– statistical analysis was performed with STATA.
Results The sample consisted of 30 women (29.7%) and 71 men
(70.3%). Mean age was 43.7 years old (SD: 8.0). Sixty-three patients
were smokers (63.6%), being the other 36 non-smokers (36.4%).
Mean dose of chlorpromazine in smokers was 1088.04mg/day
(SD: 697.17mg/day) whether in non-smokers was 699.16mg/day
(SD: 556.07mg/day). Mean differences of antipsychotic dose were
statistically significant between the two groups of smokers and
non-smokers (P = 0.005). We also found significant association
between consumption of cigarettes and antipsychotics doses
(P = 0.0001), so that, per each cigarette/day, dose of Chlorpromazine
increased 19.81mg/day.
Conclusion Patients suffering from PD smoke required higher
doses of antipsychotics. These results suggest that patients who
smoke might need higher doses of antipsychotic and that, if con-
sumption of tobacco varies, antipsychotics doses might need to be
adjusted.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1031
Metabolic syndrome and its
association with psychotropic
medications in psychiatric patients
from CAISM–IGSS (Center for
Comprehensive Care Mental
Health/Guatemalan Institute of Social
Security)
J. Lopez
Guatemala
Introduction The use of antipsychotics represents an integral
part of the psychiatric practice, unfortunately the use seems to